Ankle-Brachial Index and Peripheral Arterial Disease

C. Lamina; C. Meisinger; I. M. Heid; B. Rantner; A. Döring; H. Löwel; H. E. Wichmann; F. Kronenberg

doi:10.1055/s-2005-858244

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000022.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Gesundheitswesen 2005; 67: 57-61
DOI: 10.1055/s-2005-858244

Übersicht

Ankle-Brachial Index and Peripheral Arterial Disease

Knöchel-Arm-Index und periphere arterielle VerschlusskrankheitC. Lamina¹ , C. Meisinger¹ , I. M. Heid¹ , B. Rantner² , A. Döring¹ , H. Löwel¹ , H. E. Wichmann¹ , F. Kronenberg1, ²

¹GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg, Germany
²Innsbruck Medical University, Department of Medical Genetics, Molecular and Clinical Pharmacology, Division of Genetic Epidemiology, Innsbruck, Austria

Further Information

Publication History

Publication Date:
19 July 2005 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Zusammenfassung

Patienten mit peripherer Arteriosklerose und insbesondere solche mit Claudicatio intermittens haben ein deutlich erhöhtes Risiko für kardio- und zerebrovaskuläre Morbidität und Mortalität. Das Schicksal dieser Patienten wird weniger durch lokale Komplikationen im Bein als durch systemische Komplikationen im Bereich der koronaren und der zerebralen Gefäße geprägt. Durch Untersuchungen in der KORA-Studie 2004/2005 (F3), einer Nachuntersuchung der Teilnehmer der MONICA-Studie 1994/1995 (S3), werden wir versuchen, biochemische sowie genetische Risikofaktoren für die periphere arterielle Verschlusskrankheit zu identifizieren. Einer der uns besonders interessierenden Kandidaten ist das antiatherogene Apolipoprotein A-IV.

Abstract

Patients with peripheral arterial disease including those with intermittent claudication have a high risk for cardiovascular and cerebrovascular morbidity and mortality. The outcome of patients with intermittent claudication is less limited by local complications in the leg than by the systemic complications of coronary and cerebral vessels. About 30 % of these patients will die within 5 years, three-quarters of them due to vascular events. Analyses using data of the KORA Study 2004/2005 (F3), a follow-up examination of the participants of the MONICA Survey 1994/95 (S3), will try to identify biochemical as well as genetic risk factors for peripheral arterial disease. The anti-atherogenic apolipoprotein A-IV will be one of our candidates of interest.

Schlüsselwörter

Periphere Atherosklerose - Claudicatio intermittens - KORA - Genetik - Apolipoprotein A-IV

Key words

Peripheral arterial disease - intermittent claudication - KORA - genetics - apolipoprotein A-IV

References

1 Management of peripheral arterial disease (PAD) . TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000; 19 (Suppl 1) 1-304

PubMed Search in Google Scholar
2 Kazamias T M, Gander M P, Franklin D L. et al . Blood pressure measurement with Doppler ultrasonic flowmeter. J Appl Physiol. 1971; 30 585-588

PubMed Search in Google Scholar
3 Stegall H F, Kardon M B, Kemmerer W T. Indirect measurment of arterial blood pressure by Doppler ultrasonic sphygmomanometry. J Appl Physiol. 1968; 25 793-798

PubMed Search in Google Scholar
4 Fowkes F G, Housley E, Macintyre C C. et al . Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health. 1988; 42 128-133

PubMed Search in Google Scholar
5 Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis. 1981; 34 261-269

PubMed Search in Google Scholar
6 Laing S, Greenhalgh R M. The detection and progression of asymptomatic peripheral arterial disease. Br J Surg. 1983; 70 628-630

Crossref PubMed Search in Google Scholar
7 Carter S A. Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities. Circulation. 1968; 37 624-637

Crossref PubMed Search in Google Scholar
8 Leng G C, Fowkes F G. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992; 45 1101-1109

PubMed Search in Google Scholar
9 Hiatt W R, Hoag S, Hamman R F. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995; 91 1472-1479

Crossref PubMed Search in Google Scholar
10 Diehm C, Schuster A, Allenberg J R. et al . High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004; 172 95-105

Crossref PubMed Search in Google Scholar
11 Meijer W T, Hoes A W, Rutgers D. et al . Peripheral arterial disease in the elderly - The Rotterdam study. Arterioscler Thromb Vasc Biol. 1998; 18 185-192

Crossref PubMed Search in Google Scholar
12 Murabito J M, D’Agostino R B, Silbershatz H. et al . Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997; 96 44-49

Crossref PubMed Search in Google Scholar
13 Hughson W G, Mann J I, Garrod A. Intermittent claudication: prevalence and risk factors. BMJ. 1978; 1 1379-1381

PubMed Search in Google Scholar
14 Hertzer N R, Beven E G, Young J R. et al . Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg. 1984; 199 223-233

Crossref PubMed Search in Google Scholar
15 Crawford E S, Bomberger R A, Glaeser D H. et al . Aortoiliac occlusive disease: factors influencing survival and function following reconstructive operation over a twenty-five-year period. Surgery. 1981; 90 1055-1067

PubMed Search in Google Scholar
16 Aronow W S, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994; 74 64-65

Crossref PubMed Search in Google Scholar
17 Murabito J M, Evans J C, Nieto K. et al . Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002; 143 961-965

Crossref PubMed Search in Google Scholar
18 Jönsson B, Skau T. Ankle-brachial index and mortality in a cohort of questionnaire recorded leg pain on walking. Eur J Vasc Endovasc Surg. 2002; 24 405-410

Crossref PubMed Search in Google Scholar
19 Jager A, Kostense P J, Ruhe H G. et al . Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999; 19 617-624

PubMed Search in Google Scholar
20 Muluk S C, Muluk V S, Kelley M E. et al . Outcome events in patients with claudication: a 15-year study in 2777 patients. J Vasc Surg. 2001; 33 251-257

PubMed Search in Google Scholar
21 Labs K H, Dormandy J A, Jaeger K A. et al . Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg. 1999; 18 253-265

Crossref PubMed Search in Google Scholar
22 Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. solation and quantification. Eur J Biochem. 1979; 99 333-343

Crossref PubMed Search in Google Scholar
23 Stein O, Stein Y, Lefevre M. et al . The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from another analog of phosphatidylcholine. Biochim Biophys Acta. 1986; 878 7-13

PubMed Search in Google Scholar
24 Steinmetz A, Barbaras R, Ghalim N. et al . Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem. 1990; 265 7859-7863

PubMed Search in Google Scholar
25 Steinmetz A, Utermann G. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem. 1985; 260 2258-2264

PubMed Search in Google Scholar
26 Chen C H, Albers J J. Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3 and A-IV isolated from human plasma. Biochim Biophys Acta. 1985; 836 279-285

PubMed Search in Google Scholar
27 Goldberg I J, Scheraldi C A, Yacoub L K. et al . Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem. 1990; 265 4266-4272

PubMed Search in Google Scholar
28 Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoproteins A-I, A-II, and A- IV on cholesteryl ester transfer protein activity. J Lipid Res. 1994; 35 982-992

PubMed Search in Google Scholar
29 Qin X F, Swertfeger D K, Zheng S Q. et al . Apolipoprotein AIV: A potent endogenous inhibitor of lipid oxidation. Am J Physiol. 1998; 274 H1836-H1840

PubMed Search in Google Scholar
30 Ostos M A, Conconi M, Vergnes L. et al . Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21 1023-1028

PubMed Search in Google Scholar
31 Drazen D L, Woods S C. Peripheral signals in the control of satiety and hunger. Curr Opin Clin Nutr Metab Care. 2003; 6 621-629

PubMed Search in Google Scholar
32 Lefevre M, Lovejoy J C, DeFelice S M. et al . Common apolipoprotein A-IV variants are associated with differences in body mass index levels and percentage body fat. Int J Obes Relat Metab Disord. 2000; 24 945-953

Crossref PubMed Search in Google Scholar
33 Fiegenbaum M, Hutz M H. Further evidence for the association between obesity-related traits and the apolipoprotein A-IV gene. Int J Obes Relat Metab Disord. 2003; 27 484-490

PubMed Search in Google Scholar
34 Lingenhel A, Eder C, Zwiauer K. et al . Decrease of plasma apolipoprotein A-IV during weight reduction in obese adolescents on a low fat diet. Int J Obes. 2004; 28 1509-1513

Crossref PubMed Search in Google Scholar
35 Duverger N, Tremp G, Caillaud J M. et al . Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996; 273 966-968

PubMed Search in Google Scholar
36 Cohen R D, Castellani L W, Qiao J H. et al . Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 1997; 99 1906-1916

PubMed Search in Google Scholar
37 Kronenberg F, Stühlinger M, Trenkwalder E. et al . Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol. 2000; 36 751-757

PubMed Search in Google Scholar
38 Duverger N, Ghalim N, Ailhaud G. et al . Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb. 1993; 13 126-132

PubMed Search in Google Scholar
39 Von Eckardstein A, Huang Y, Wu S. et al . Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol. 1995; 15 1755-1763

PubMed Search in Google Scholar
40 Kronenberg F, Kuen E, Ritz E. et al . Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. J Am Soc Nephrol. 2002; 13 461-469

PubMed Search in Google Scholar
41 Ezeh B, Haiman M, Alber H F. et al . Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res. 2003; 44 1523-1529

PubMed Search in Google Scholar
42 Wong W M, Hawe E, Li L K. et al . Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003; 92 969-975

Crossref PubMed Search in Google Scholar

Florian Kronenberg, MD

Innsbruck Medical University, Department of Medical Genetics, Molecular and Clinical Pharmacology, Division of Genetic Epidemiology

Schöpfstraße 41

6020 Innsbruck

Austria